Exco InTouch Partners With Oracle Health Sciences
News Mar 11, 2016
Exco InTouch has announced the standardized integration between two “best of breed” solutions to provide a robust, highly integrated electronic data capture (EDC) and electronic patient reported outcomes (ePRO) solution which provides the market with a resource that streamlines workflow processes in clinical research.
The integration of Exco InTouch’s patient engagement platform with Oracle Health Sciences’ market-leading InForm EDC system will deliver enhanced workflow efficiency and improve data quality during clinical trials. Together, through a seamless standards-based service orientated architecture (SOA) integration, this platform provides a complete data capture solution for both clinical and post-marketing studies. For sponsors, CROs and investigator sites, the result is a significant improvement to patient retention, adherence and the overall quality of study data.
This highly innovative solution brings multiple benefits to the market. Site and patient captured clinical data, including that taken directly from medical devices, is seamlessly integrated resulting in much more accurate and timely data reporting for clinicians. Furthermore, this approach introduces the opportunity to leverage smartphone technology, removing the need to provide patients with specialized, expensive devices.
Underpinned by patented technology, clients can take advantage of a Bring Your Own Device (BYOD) strategy, which enables patients to use their own mobile devices. This is particularly valuable in late phase trials, where the cost of provisioning devices prohibits the use of electronic data capture. This initiative also drives engagement by providing a tailored suite of communication, informational and reporting services throughout the patient journey.
The solution created through this joint initiative is set to support sponsors, clinicians and patients through the collection of more accurate and complete study data, significantly reduced logistical complexity and increase patient compliance to trial protocols.
Martin Cook, VP of Strategic Partnerships, Exco InTouch, commented “We are delighted to have formed this strategic partnership with Oracle and, as a consequence of this initiative, to be able to bring highly beneficial innovation to the market with the capability to optimize work flow efficiency and to improve the quality of data captured, both in clinical research and real world health programs.”
Martin continues: “We are excited by what this partnership has brought to the market. Combining Oracle’s Inform system with Exco InTouch’s patient engagement technology puts a new solution into the hands of sponsors, clinicians and patients with efficiency benefits that ultimately improve clinical research outcomes. We very much look forward to rolling out our joint solution.”
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019